Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties
Resumen: New organometallic gold(III) and platinum(II) complexes containing iminophosphorane ligands are described. Most of them are more cytotoxic to a number of human cancer cell lines than cisplatin. Cationic Pt(II) derivatives 4 and 5, which differ only in the anion, Hg2Cl62– or PF6– respectively, display almost identical IC50 values in the sub-micromolar range (25–335-fold more active than cisplatin on these cell lines). The gold compounds induced mainly caspase-independent cell death, as previously reported for related cycloaurated compounds containing IM ligands. Cycloplatinated compounds 3, 4, and 5 can also activate alternative caspase-independent mechanisms of death. However, at short incubation times cell death seems to be mainly caspase dependent, suggesting that the main mechanism of cell death for these compounds is apoptosis. Mercury-free compound 5 does not interact with plasmid (pBR322) DNA or with calf thymus DNA. Permeability studies of 5 by two different assays, in vitro Caco-2 monolayers and a rat perfusion model, have revealed a high permeability profile for this compound (comparable to that of metoprolol or caffeine) and an estimated oral fraction absorbed of 100%, which potentially makes it a good candidate for oral administration.
Idioma: Inglés
DOI: 10.1021/acs.jmedchem.5b00427
Año: 2015
Publicado en: Journal of medicinal chemistry 58, 15 (2015), 5825-5841
ISSN: 0022-2623

Factor impacto JCR: 5.589 (2015)
Categ. JCR: CHEMISTRY, MEDICINAL rank: 3 / 59 = 0.051 (2015) - Q1 - T1
Factor impacto SCIMAGO: 2.446 - Molecular Medicine (Q1) - Drug Discovery (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MEC/FPU-AP2010-2372
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2010-1490
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial.


Exportado de SIDERAL (2021-01-21-11:20:47)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2020-01-03, última modificación el 2021-01-21


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)